Comparison of Sinemet CR4 and standard Sinemet: Double blind and long‐term open trial in parkinsonian patients with fluctuations
Identifieur interne : 006465 ( Main/Exploration ); précédent : 006464; suivant : 006466Comparison of Sinemet CR4 and standard Sinemet: Double blind and long‐term open trial in parkinsonian patients with fluctuations
Auteurs : Jankovic [États-Unis] ; Kenneth Schwartz [États-Unis] ; Chris Vander Linden [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 1989.
English descriptors
- KwdEn :
- Aged, Antiparkinson Agents (administration & dosage), Antiparkinson Agents (pharmacology), Carbidopa, Carbidopa (administration & dosage), Carbidopa (pharmacology), Delayed-Action Preparations, Double-Blind Method, Drug Combinations (administration & dosage), Drug Combinations (pharmacology), Humans, Levodopa, Levodopa (administration & dosage), Levodopa (pharmacology), Middle Aged, Movement (drug effects), Parkinson Disease (drug therapy), Parkinson Disease (physiopathology), Parkinson's disease, Randomized Controlled Trials as Topic, Sinemet CR4, Standard Sinemet.
- MESH :
- chemical , administration & dosage : Antiparkinson Agents, Carbidopa, Drug Combinations, Levodopa.
- chemical , pharmacology : Antiparkinson Agents, Carbidopa, Drug Combinations, Levodopa.
- drug effects : Movement.
- drug therapy : Parkinson Disease.
- physiopathology : Parkinson Disease.
- Aged, Delayed-Action Preparations, Double-Blind Method, Humans, Middle Aged, Randomized Controlled Trials as Topic.
Abstract
“Wearing‐off” effect, the most common form of levodopa‐induced fluctuations, seems to be related to the short plasma half‐life of the drug. More sustained plasma levodopa levels may be achieved with a new controlledrelease formulation of carbidopa/levodopa, Sinemet CR4. We studied 20 patients, 12 men and 8 women, with Parkinson's disease complicated by “wearing‐off” phenomenon. Mean age was 61.1 ± 8.1 years, duration of symptoms 8.3 ± 2.4 years, and the Hoehn‐Yahr stage 3.0 ± 0.9. In a 12‐week double‐blind study, the average number of tablets administered per day decreased from 5.7 ± 1.2 to 3.8 ± 0.7 when Sinemet CR4 (50/200) was substituted for the standard Sinemet (25/100) (p < 0.001). However, this was at the expense of reducing the “on” time (without dyskinesia) from 9.3 ± 4.6 to 7.5 ± 4.3 (p < 0.05), although the total “on” time did not significantly change. In a long‐term follow‐up of 18 patients, the “on” time with dyskinesia and morning dystonia significantly increased (p < 0.05). There was no significant change in the total daily dosage of levodopa, but the daily number of doses and tablets significantly decreased (p < 0.001). Despite increased dyskinesia, most patients preferred taking fewer tablets and have elected to continue taking Sinemet CR4 instead of standard Sinemet. Sinemet CR4 seems to offer a new and effective strategy for the management of levodopa‐related fluctuations.
Url:
DOI: 10.1002/mds.870040403
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002557
- to stream Istex, to step Curation: 002557
- to stream Istex, to step Checkpoint: 004495
- to stream PubMed, to step Corpus: 004F81
- to stream PubMed, to step Curation: 004F81
- to stream PubMed, to step Checkpoint: 004F92
- to stream Ncbi, to step Merge: 004527
- to stream Ncbi, to step Curation: 004527
- to stream Ncbi, to step Checkpoint: 004527
- to stream Main, to step Merge: 009818
- to stream Main, to step Curation: 006465
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Comparison of Sinemet CR4 and standard Sinemet: Double blind and long‐term open trial in parkinsonian patients with fluctuations</title><author><name sortKey="Jankovic" sort="Jankovic" uniqKey="Jankovic" last="Jankovic">Jankovic</name></author><author><name sortKey="Schwartz, Kenneth" sort="Schwartz, Kenneth" uniqKey="Schwartz K" first="Kenneth" last="Schwartz">Kenneth Schwartz</name></author><author><name sortKey="Linden, Chris Vander" sort="Linden, Chris Vander" uniqKey="Linden C" first="Chris Vander" last="Linden">Chris Vander Linden</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:13E84E2DC67FE56B5CD66A36FBC7D0F6E9C3C383</idno><date when="1989" year="1989">1989</date><idno type="doi">10.1002/mds.870040403</idno><idno type="url">https://api.istex.fr/document/13E84E2DC67FE56B5CD66A36FBC7D0F6E9C3C383/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002557</idno><idno type="wicri:Area/Istex/Curation">002557</idno><idno type="wicri:Area/Istex/Checkpoint">004495</idno><idno type="wicri:doubleKey">0885-3185:1989:Jankovic:comparison:of:sinemet</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:2682215</idno><idno type="wicri:Area/PubMed/Corpus">004F81</idno><idno type="wicri:Area/PubMed/Curation">004F81</idno><idno type="wicri:Area/PubMed/Checkpoint">004F92</idno><idno type="wicri:Area/Ncbi/Merge">004527</idno><idno type="wicri:Area/Ncbi/Curation">004527</idno><idno type="wicri:Area/Ncbi/Checkpoint">004527</idno><idno type="wicri:doubleKey">0885-3185:1989:Jankovic J:comparison:of:sinemet</idno><idno type="wicri:Area/Main/Merge">009818</idno><idno type="wicri:Area/Main/Curation">006465</idno><idno type="wicri:Area/Main/Exploration">006465</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Comparison of Sinemet CR4 and standard Sinemet: Double blind and long‐term open trial in parkinsonian patients with fluctuations</title><author><name sortKey="Jankovic" sort="Jankovic" uniqKey="Jankovic" last="Jankovic">Jankovic</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Baylor College of Medicine, Houston, Texas</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Schwartz, Kenneth" sort="Schwartz, Kenneth" uniqKey="Schwartz K" first="Kenneth" last="Schwartz">Kenneth Schwartz</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Baylor College of Medicine, Houston, Texas</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Linden, Chris Vander" sort="Linden, Chris Vander" uniqKey="Linden C" first="Chris Vander" last="Linden">Chris Vander Linden</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Baylor College of Medicine, Houston, Texas</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1989">1989</date><biblScope unit="vol">4</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="303">303</biblScope><biblScope unit="page" to="309">309</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">13E84E2DC67FE56B5CD66A36FBC7D0F6E9C3C383</idno><idno type="DOI">10.1002/mds.870040403</idno><idno type="ArticleID">MDS870040403</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antiparkinson Agents (administration & dosage)</term><term>Antiparkinson Agents (pharmacology)</term><term>Carbidopa</term><term>Carbidopa (administration & dosage)</term><term>Carbidopa (pharmacology)</term><term>Delayed-Action Preparations</term><term>Double-Blind Method</term><term>Drug Combinations (administration & dosage)</term><term>Drug Combinations (pharmacology)</term><term>Humans</term><term>Levodopa</term><term>Levodopa (administration & dosage)</term><term>Levodopa (pharmacology)</term><term>Middle Aged</term><term>Movement (drug effects)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (physiopathology)</term><term>Parkinson's disease</term><term>Randomized Controlled Trials as Topic</term><term>Sinemet CR4</term><term>Standard Sinemet</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term><term>Carbidopa</term><term>Drug Combinations</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiparkinson Agents</term><term>Carbidopa</term><term>Drug Combinations</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Movement</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Delayed-Action Preparations</term><term>Double-Blind Method</term><term>Humans</term><term>Middle Aged</term><term>Randomized Controlled Trials as Topic</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">“Wearing‐off” effect, the most common form of levodopa‐induced fluctuations, seems to be related to the short plasma half‐life of the drug. More sustained plasma levodopa levels may be achieved with a new controlledrelease formulation of carbidopa/levodopa, Sinemet CR4. We studied 20 patients, 12 men and 8 women, with Parkinson's disease complicated by “wearing‐off” phenomenon. Mean age was 61.1 ± 8.1 years, duration of symptoms 8.3 ± 2.4 years, and the Hoehn‐Yahr stage 3.0 ± 0.9. In a 12‐week double‐blind study, the average number of tablets administered per day decreased from 5.7 ± 1.2 to 3.8 ± 0.7 when Sinemet CR4 (50/200) was substituted for the standard Sinemet (25/100) (p < 0.001). However, this was at the expense of reducing the “on” time (without dyskinesia) from 9.3 ± 4.6 to 7.5 ± 4.3 (p < 0.05), although the total “on” time did not significantly change. In a long‐term follow‐up of 18 patients, the “on” time with dyskinesia and morning dystonia significantly increased (p < 0.05). There was no significant change in the total daily dosage of levodopa, but the daily number of doses and tablets significantly decreased (p < 0.001). Despite increased dyskinesia, most patients preferred taking fewer tablets and have elected to continue taking Sinemet CR4 instead of standard Sinemet. Sinemet CR4 seems to offer a new and effective strategy for the management of levodopa‐related fluctuations.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Texas</li></region></list><tree><country name="États-Unis"><region name="Texas"><name sortKey="Jankovic" sort="Jankovic" uniqKey="Jankovic" last="Jankovic">Jankovic</name></region><name sortKey="Linden, Chris Vander" sort="Linden, Chris Vander" uniqKey="Linden C" first="Chris Vander" last="Linden">Chris Vander Linden</name><name sortKey="Schwartz, Kenneth" sort="Schwartz, Kenneth" uniqKey="Schwartz K" first="Kenneth" last="Schwartz">Kenneth Schwartz</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006465 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 006465 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:13E84E2DC67FE56B5CD66A36FBC7D0F6E9C3C383
|texte= Comparison of Sinemet CR4 and standard Sinemet: Double blind and long‐term open trial in parkinsonian patients with fluctuations
}}
| This area was generated with Dilib version V0.6.23. |  |